Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

E1018

Phase 1Small molecule

E1018 is one of 27 small molecule programs targeting Malaria. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

26

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

79 competitors in Malaria

#DrugCompanyPhaseTrials

Tybost

Dihydroartemisinin-Piperaquine

Rabies Vaccine

Krintafel

GGlaxo Dba Glaxosmithkline

Artemether-Lumefantrine (AL)

Artesunate-Amodiaquine

R21/matrix-M

UUniversity of Oxford

Pyramax

SShin Poong Pharmaceutical Co. Ltd.

Biltricide

Stelara

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Malaria

NCT06854042

Clinical

Trials by Indication[1]

Malaria1 trial

A First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral E1018 in Healthy Adult Subjects

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT06854042·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for E1018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E1018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E1018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

Related News